Affiliations: Department of Medicine, Clinical Division of Oncology, Comprehensive Cancer Center of the Medical University of Vienna, Vienna, Austria | [x] The University of Medicine and Pharmacy Iuliu Hatieganu, Cluj, Napoca, Romania | [y] National Cancer Research Center, Istituto Tumori G Paolo II, IRCCS, Bari, Italy
Correspondence:
[*]
Corresponding author: Robert M. Mader, Department of Medicine I, Clinical Division of Oncology, Comprehensive Cancer Center of the Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. Tel.: +43 1 40400 5466; Fax: +43 1 40400 6081; E-mail: [email protected].
Abstract: The rapidly evolving understanding of tumour biology offers novel opportunities for therapeutic interventions. This information already has been used to select appropriate systemic treatment. To take full advantage of this knowledge, however, the different levels of interaction in an organism need to be integrated to link cellular mechanisms, stromal effects and the implications for organs and the whole organism. Although very challenging and ambitious, this understanding would closely link tumour biology, biomarker validation and rational therapeutic decisions.
Keywords: Cancer biology, predictive biomarkers, translational research
